An 
improved method and products for the primary hormonal treatment of early stage, low and intermediate risk 
prostate cancers by prostatic implants of 
androgen suppressive drugs formulated as fused with a lipoid carrier or encapsulated in microcapsules or in 
Silastic capsules is provided. Such prostatic implants renders a constant slow-release of their contents to the 
prostate for extended periods by 
biodegradation and 
diffusion. It facilitates higher prostatic and lower systemic concentrations of 
androgen suppressive hormones. Because of their high prostatic and lower systemic concentrations, 
tumor control is much improved and the their 
systemic toxicity is minimized. 
Tumor control after such primary hormonal 
implant treatment is followed by clinical examinations and the biochemical 
tumor control is followed by periodic estimations of serum levels of PSA and 
acid phosphatase. More complex and expensive 
surgery or 
radiation therapy for this group of good prognostic early stage 
prostate cancer is reserved for those patients failing to this primary hormonal treatment. It will preserve 
potency more than by 
surgery or 
radiation therapy. Furthermore, it would reduce the 
cost of treatment for early stage 
prostate cancer significantly. 
Androgen suppressive hormonal implants to the prostate before, during or after lower 
dose conventional 
radiation therapy would also facilitate equal or better cure rates of localized 
prostate cancer as compared to the more complex and toxic higher 
dose radiation therapy.